<?xml version='1.0' encoding='utf-8'?>
<document id="6590529"><sentence text="Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1."><entity charOffset="11-24" id="DDI-PubMed.6590529.s1.e0" text="harringtonine" /><entity charOffset="45-53" id="DDI-PubMed.6590529.s1.e1" text="acivicin" /><entity charOffset="55-65" id="DDI-PubMed.6590529.s1.e2" text="adriamycin" /><entity charOffset="83-103" id="DDI-PubMed.6590529.s1.e3" text="cytosine arabinoside" /><entity charOffset="105-118" id="DDI-PubMed.6590529.s1.e4" text="dexamethasone" /><entity charOffset="120-132" id="DDI-PubMed.6590529.s1.e5" text="fluorouracil" /><entity charOffset="136-148" id="DDI-PubMed.6590529.s1.e6" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e0" e2="DDI-PubMed.6590529.s1.e0" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e0" e2="DDI-PubMed.6590529.s1.e1" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e0" e2="DDI-PubMed.6590529.s1.e2" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e0" e2="DDI-PubMed.6590529.s1.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e0" e2="DDI-PubMed.6590529.s1.e4" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e0" e2="DDI-PubMed.6590529.s1.e5" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e0" e2="DDI-PubMed.6590529.s1.e6" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e1" e2="DDI-PubMed.6590529.s1.e1" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e1" e2="DDI-PubMed.6590529.s1.e2" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e1" e2="DDI-PubMed.6590529.s1.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e1" e2="DDI-PubMed.6590529.s1.e4" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e1" e2="DDI-PubMed.6590529.s1.e5" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e1" e2="DDI-PubMed.6590529.s1.e6" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e2" e2="DDI-PubMed.6590529.s1.e2" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e2" e2="DDI-PubMed.6590529.s1.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e2" e2="DDI-PubMed.6590529.s1.e4" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e2" e2="DDI-PubMed.6590529.s1.e5" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e2" e2="DDI-PubMed.6590529.s1.e6" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e3" e2="DDI-PubMed.6590529.s1.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e3" e2="DDI-PubMed.6590529.s1.e4" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e3" e2="DDI-PubMed.6590529.s1.e5" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e3" e2="DDI-PubMed.6590529.s1.e6" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e4" e2="DDI-PubMed.6590529.s1.e4" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e4" e2="DDI-PubMed.6590529.s1.e5" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e4" e2="DDI-PubMed.6590529.s1.e6" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e5" e2="DDI-PubMed.6590529.s1.e5" /><pair ddi="false" e1="DDI-PubMed.6590529.s1.e5" e2="DDI-PubMed.6590529.s1.e6" /></sentence><sentence text="Harringtonine (HT) is a new antitumor agent reported to be active in patients with leukemia and lymphoma"><entity charOffset="0-13" id="DDI-PubMed.6590529.s2.e0" text="Harringtonine" /><entity charOffset="15-17" id="DDI-PubMed.6590529.s2.e1" text="HT" /><pair ddi="false" e1="DDI-PubMed.6590529.s2.e0" e2="DDI-PubMed.6590529.s2.e0" /><pair ddi="false" e1="DDI-PubMed.6590529.s2.e0" e2="DDI-PubMed.6590529.s2.e1" /></sentence><sentence text=" The interaction of HT with various antitumor agents was studied in vitro using a human acute myelogenous leukemia cell line KG-1"><entity charOffset="20-21" id="DDI-PubMed.6590529.s3.e0" text="HT" /></sentence><sentence text=" For the analysis of the drug - drug interaction at the cellular level, Steel proposed the concept of an envelope of additivity" /><sentence text=" Using this concept, the effect of a two drug combination can be classified as supraadditive (enhancement of the effect), non-interactive (additive), subadditive, and protective (antagonistic)" /><sentence text=" Combination of HT and cytosine arabinoside or HT and dexamethasone produced only additive effects"><entity charOffset="16-18" id="DDI-PubMed.6590529.s6.e0" text="HT" /><entity charOffset="23-43" id="DDI-PubMed.6590529.s6.e1" text="cytosine arabinoside" /><entity charOffset="47-49" id="DDI-PubMed.6590529.s6.e2" text="HT" /><entity charOffset="54-67" id="DDI-PubMed.6590529.s6.e3" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e0" e2="DDI-PubMed.6590529.s6.e0" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e0" e2="DDI-PubMed.6590529.s6.e1" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e0" e2="DDI-PubMed.6590529.s6.e2" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e0" e2="DDI-PubMed.6590529.s6.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e1" e2="DDI-PubMed.6590529.s6.e1" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e1" e2="DDI-PubMed.6590529.s6.e2" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e1" e2="DDI-PubMed.6590529.s6.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e2" e2="DDI-PubMed.6590529.s6.e2" /><pair ddi="false" e1="DDI-PubMed.6590529.s6.e2" e2="DDI-PubMed.6590529.s6.e3" /></sentence><sentence text=" Combination of HT and methotrexate was subadditive"><entity charOffset="16-18" id="DDI-PubMed.6590529.s7.e0" text="HT" /><entity charOffset="23-35" id="DDI-PubMed.6590529.s7.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.6590529.s7.e0" e2="DDI-PubMed.6590529.s7.e0" /><pair ddi="false" e1="DDI-PubMed.6590529.s7.e0" e2="DDI-PubMed.6590529.s7.e1" /></sentence><sentence text=" For HT plus adriamycin or HT plus 5-fluorouracil, data points indicated both subadditive and protective interaction"><entity charOffset="13-23" id="DDI-PubMed.6590529.s8.e0" text="adriamycin" /><entity charOffset="35-49" id="DDI-PubMed.6590529.s8.e1" text="5-fluorouracil" /><entity charOffset="5-18" id="DDI-PubMed.6590529.s8.e2" text="HT" /><entity charOffset="27-40" id="DDI-PubMed.6590529.s8.e3" text="HT" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e2" e2="DDI-PubMed.6590529.s8.e2" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e2" e2="DDI-PubMed.6590529.s8.e0" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e2" e2="DDI-PubMed.6590529.s8.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e2" e2="DDI-PubMed.6590529.s8.e1" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e0" e2="DDI-PubMed.6590529.s8.e0" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e0" e2="DDI-PubMed.6590529.s8.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e0" e2="DDI-PubMed.6590529.s8.e1" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e3" e2="DDI-PubMed.6590529.s8.e3" /><pair ddi="false" e1="DDI-PubMed.6590529.s8.e3" e2="DDI-PubMed.6590529.s8.e1" /></sentence><sentence text=" HT plus acivicin or HT plus L-asparaginase combinations were found to be protective of each other"><entity charOffset="9-17" id="DDI-PubMed.6590529.s9.e0" text="acivicin" /><entity charOffset="1-8" id="DDI-PubMed.6590529.s9.e1" text="HT" /><entity charOffset="21-28" id="DDI-PubMed.6590529.s9.e2" text="HT" /><pair ddi="false" e1="DDI-PubMed.6590529.s9.e1" e2="DDI-PubMed.6590529.s9.e1" /><pair ddi="false" e1="DDI-PubMed.6590529.s9.e1" e2="DDI-PubMed.6590529.s9.e0" /><pair ddi="false" e1="DDI-PubMed.6590529.s9.e1" e2="DDI-PubMed.6590529.s9.e2" /><pair ddi="false" e1="DDI-PubMed.6590529.s9.e0" e2="DDI-PubMed.6590529.s9.e0" /><pair ddi="false" e1="DDI-PubMed.6590529.s9.e0" e2="DDI-PubMed.6590529.s9.e2" /></sentence><sentence text=" None of the seven agents produced supraadditive interaction" /><sentence text=" These results may provide the basis for selecting sequential rather than concurrent combinations which include HT for the treatment of leukemia in man"><entity charOffset="112-113" id="DDI-PubMed.6590529.s11.e0" text="HT" /></sentence><sentence text="" /></document>